Status | In progress |
Process | STA 2018 |
ID number | 3816 |
Provisional Schedule
Committee meeting: 1 | 09 November 2021 |
Expected publication | 02 February 2022 |
Project Team
Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
Evidence Review Group / Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Consultees
Companies sponsors | Janssen (ciltacabtagene autoleucel) |
Others | Department of Health and Social Care |
NHS England | |
NHS Lambeth CCG | |
NHS Waltham Forest CCG | |
Welsh Government | |
Patient carer groups | African Caribbean Leukaemia Trust |
Anthony Nolan | |
Black Health Agency for Equality | |
Blood Cancer UK | |
Cancer Black Care | |
Cancer Equality | |
Cancer52 | |
DKMS | |
Helen Rollason Cancer Charity | |
Independent Cancer Patients Voice | |
Leukaemia Cancer Society | |
Leukaemia Care | |
Macmillan Cancer Support | |
Maggie’s Centres | |
Marie Curie | |
Myeloma UK | |
South Asian Health Foundation | |
Specialised Healthcare Alliance | |
Tenovus Cancer Care | |
Professional groups | Association of Cancer Physicians |
British Blood Transfusion Society | |
British Committee for Standards in Haematology | |
British Geriatrics Society | |
British Institute of Radiology | |
British Psychosocial Oncology Society | |
British Society for Haematology | |
British Society for Interventional Radiology | |
British Transplantation Society | |
Cancer Research UK | |
NHS Blood and Transplant | |
Royal College of General Practitioners | |
Royal College of Nursing | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal College of Radiologists | |
Royal Pharmaceutical Society | |
Royal Society of Medicine | |
Society and College of Radiographers | |
UK Clinical Pharmacy Association | |
UK Myeloma Forum | |
UK Oncology Nursing Society |
Commentators
Associated guideline groups | National Guideline Alliance |
Associated public health groups | Public Health England |
Public Health Wales | |
Comparator companies | Advanz pharma (dexamethasone) |
Amgen (carfilzomib) | |
Aspen (dexamethasone) | |
Aspire pharma (bortezomib, dexamethasone) | |
Celgene (lenalidomide, pomalidomide) | |
Consilient health (dexamethasone) | |
Dr Reddy’s laboratories (bortezomib) | |
Glenmark pharmaceuricals (dexamethasone) | |
Janssen-Cilag (bortezomib) | |
Martindale pharma (dexamethasone) | |
Mylan (bortezomib) | |
Novartis pharmaceuticals (panobinostat) | |
Teva (dexamethasone) | |
Thornton & Ross (bortezomib) | |
Rosemont pharmaceuticals limited (dexamethasone) | |
Zentiva (bortezomib) | |
General commentators | All Wales Therapeutics and Toxicology Centre |
Allied Health Professionals Federation | |
Board of Community Health Councils in Wales | |
British National Formulary | |
Care Quality Commission | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare Products Regulatory Agency | |
National Association of Primary Care | |
National Pharmacy Association | |
NHS Alliance | |
NHS Confederation | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Cochrane Haematological Malignancies Group |
Genomics England | |
Institute of Cancer Research | |
Leukaemia UK | |
Leukaemia Busters | |
MRC Clinical Trials Unit | |
National Cancer Research Institute | |
National Cancer Research Network | |
National Institute for Health Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
12 March 2021 | Invitation to participate |
14 January 2021 - 11 February 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
17 March 2020 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance